交易中 11-18 10:57:18 美东时间
-0.085
-6.80%
MetaVia reports positive Phase 1 data showing that once-weekly DA-1726 significantly reduces serum uric acid and liver fat.
11-13 01:40
https://www.sec.gov/Archives/edgar/data/1638287/000110465926080305/tm2618959d2_424b5.htm
07-03 04:11
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a comprehensive global intellectual property portfolio supporting vanoglipel
03-12 21:08
MetaVia shares climb Friday after securing 39 patents for its obesity drug DA-1726, with strong clinical results and protection through 2041.
02-14 01:39
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01212026_MTVA_Bautz.pdf
01-21 23:06
MetaVia Inc's (NYSE:MTVA) short interest as a percent of float has fallen 67.55...
01-19 22:00
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
01-16 01:09
U.S. stocks traded higher this morning, with the Dow Jones index gaining around...
01-15 22:57
Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54Strong Glycemic Response with a 12.3
01-05 21:32
Shares of Viasat Inc (NASDAQ:VSAT) rose sharply in pre-market trading after the...
2025-11-10 17:51